fbpx

What is your brain tumor story? Click here to share it and join the community!

A major impediment to improving brain tumor outcomes is poor clinical trial accrual. In fact, only 20 percent of neuro-oncology patients enroll in clinical trials. Surveys of brain tumor patients and neuro-oncology providers suggest that clinicians do a poor job of discussing clinical trials with patients and referring patients for clinical trials. Yet, data from the Cancer Action Network of the American Cancer Society suggest that when most eligible oncology patients are asked to enroll in a clinical trial, they will agree to do so.

Only 20 percent of neuro-oncology patients enroll in clinical trials.

The Society for Neuro-Oncology (SNO) in collaboration with the Response Assessment in Neuro-Oncology (RANO) Working Group, patient advocacy groups including the American Brain Tumor Association, clinical trial cooperative groups including the Adult Brain Tumor Consortium (ABTC), and other partners are working together with the intent to double clinical trial accrual over the next five years.

This collaborative group reviewed the literature and held several working group calls to discuss the barriers to clinical trial accrual as well as potential solutions to decreasing these barriers to participation in brain tumor clinical trials.

Some of those solutions include:

This data was recently accepted for publication in the journal of Neuro-Oncology. The abstract for the article can be accessed here.